Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors
Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors
复制标题
DOI：
10.1007/s11060-012-0837-0
复制
发表时间：
2012-07-01
影响因子：
3.9
通讯作者：
Matsumura, Akira
中科院分区：
文献类型：
--
作者：
Takano, Shingo;Kato, Yukinari;Matsumura, Akira
异柠檬酸脱氢酶1（IDH 1）突变是星形细胞瘤、少突胶质细胞瘤、少突星形细胞瘤和继发性胶质母细胞瘤的早期和常见遗传改变，对精氨酸132（R132）具有特异性。最近，我们建立了针对IDH 1突变的单克隆抗体（mAb）：抗IDH 1-R132 H和抗IDH 1-R132 S。然而，使用这些mAb的组合的免疫组织化学的重要性尚未阐明。在这项研究中，使用抗IDH 1单克隆抗体（HMab-1和SMab-1）对164例胶质瘤进行了IDH 1突变（R132 H和R132 S）的化学评价。在原发性IV级、继发性IV级、III级和II级胶质瘤中分别检测到9.7%、63.6%、51.7%和77.8%的IDH 1突变。对于每个级别的胶质瘤，使用临床和病理学参数以及IDH 1免疫组化评估无进展生存期和总生存期的预后因素。IDH 1突变，p53过表达，internexin表达，使用免疫组化与临床参数，如手术切除程度和术前Karnofsky性能状态（KPS）进行评估，可能比单独的组织学分级在III级以及IDH 1突变在IV级胶质瘤的预后意义更大。
Isocitrate dehydrogenase 1 (IDH1) mutations, which are early and frequent genetic alterations in astrocytomas, oligodendrogliomas, oligoastrocytomas, and secondary glioblastomas, are specific to arginine 132 (R132). Recently, we established monoclonal antibodies (mAbs) against IDH1 mutations: anti-IDH1-R132H and anti-IDH1-R132S. However, the importance of immunohistochemistry using the combination of those mAbs has not been elucidated. For this study, 164 cases of glioma were evaluated immunohistochemically for IDH1 mutations (R132H and R132S) using anti-IDH1 mAbs (HMab-1 and SMab-1). IDH1 mutation was detected, respectively, in 9.7%, 63.6%, 51.7%, and 77.8% of primary grade IV, secondary grade IV, grade III, and grade II gliomas. For each grade of glioma, prognostic factors for progression-free survival and overall survival were evaluated using clinical and pathological parameters in addition to IDH1 immunohistochemistry. IDH1 mutation, p53 overexpression, and internexin expression, as evaluated using immunohistochemistry with clinical parameters such as degree of surgical removal and preoperative Karnofsky Performance Status (KPS), might be of greater prognostic significance than histological grading alone in grade III as well as IDH1 mutation in grade IV gliomas.